{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-036343","form_type":"8-K/A","ticker":"BLFS","cik":"0000834365","company_name":"BIOLIFE SOLUTIONS INC","filed_at":"2024-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.016459+00:00","generated_at":"2026-05-31T10:37:24.023474+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioLife Solutions corrects Q2 earnings; raises full-year revenue guidance to $99-101M","bullets":["Q2 total revenue $28.3M, down 3% YoY but up 6% sequentially; Cell Processing up 11% sequentially.","GAAP net loss from continuing ops $7.1M (incl $4.1M write-off) versus $5.5M loss a year ago.","Non-GAAP adjusted EBITDA $4.8M or 17% of revenue, up from $1.7M or 6% in Q2 2023.","FY 2024 total revenue guidance raised to $99-101M; Cell Processing guidance raised to $70-71M.","8-K/A corrects prior release to reduce stock compensation by $2.1M from discontinued operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-036343","json":"https://secwatch.observer/filing/0001628280-24-036343.json","markdown":"https://secwatch.observer/filing/0001628280-24-036343.md","text":"https://secwatch.observer/filing/0001628280-24-036343.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/834365/000162828024036343/0001628280-24-036343-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/834365/000162828024036343/blfs-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:37:24.023474+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}